Innova Captab Quarterly Results for Trading Insights
In Mar 2026, Innova Captab (INNOVACAP) reported revenue ₹449 Cr and net profit ₹38 Cr — revenue +41.2% YoY. For annual financials, live price and key ratios, visit Innova Captab share price screener.
INNOVACAP Quarterly Results — Revenue, Profit & EPS Highlights
Innova Captab latest quarter revenue, net profit, EPS and QoQ/YoY growth rates. Analyse Innova Captab shareholding analysis to track promoter, FII and institutional holdings.
- Revenue of ₹449 Cr in Mar 2026 (-5.1% vs Jun 2026, +41.2% vs Mar 2025)
- Net Profit of ₹38 Cr in Mar 2026 (-13.6% vs Jun 2026, +26.7% vs Mar 2025)
- EBITDA of ₹67 Cr in Mar 2026 (-10.7% vs Jun 2026)
- Operating Margin of 15.0% in Mar 2026 (-1.0pp vs Jun 2026)
- Earnings Per Share of ₹6.65 in Mar 2026 (-13.7% vs Jun 2026)
Innova Captab Quarterly Results — Revenue, EBITDA, Net Profit & EPS
INNOVACAP quarterly revenue, expenses, EBITDA, net profit, EPS and operating margin with QoQ and YoY comparison.
| Metric | Mar 2026 | Jun 2026 | Sept 2025 | Mar 2025 | Jun 2025 | QoQ | YoY |
|---|---|---|---|---|---|---|---|
| Revenue (₹ Cr) | 449 | 473 | 385 | 318 | 356 | -5.1% | 41.2% |
| Net Profit (₹ Cr) | 38 | 44 | 30 | 30 | 31 | - | - |
| EBITDA (₹ Cr) | 67 | 75 | 56 | 51 | 57 | - | - |
| EPS (₹) | 6.65 | 7.71 | 5.18 | 5.17 | 5.42 | - | - |
| Operating Margin (%) | 15.0% | 16.0% | 14.0% | 15.0% | 15.0% | - | - |
INNOVACAP Share Price Trend — 1-Year Movement Across Quarterly Results
Innova Captab 1-year share price in ₹ overlaid with quarterly earnings dates — NSE/BSE closing prices. View Innova Captab yearly highs lows for the annual high/low range and current price position.
Revenue Trend (₹ Cr)
Net Profit Trend (₹ Cr)
Operating Margin Trend (%)
INNOVACAP vs Healthcare Peers — Quarterly Revenue, Profit & Market Cap
Innova Captab latest quarter revenue and net profit vs Healthcare competitors — market cap, price and earnings comparison.
| Company Latest Quarter | Market Cap (₹ Cr) | Price (₹) | Revenue (₹ Cr) | Net Profit (₹ Cr) | Rev QoQ % | Rev YoY % | Profit Margin % | P/E Ratio |
|---|---|---|---|---|---|---|---|---|
|
Sun Pharmaceutical
Mar 2026 |
₹441,477.63 Cr | 1837.3 | 15,018 | 2,710 | -5.6% | - | 18.0% | 162.6 |
|
Divis Laboratories
Mar 2026 |
₹247,469.81 Cr | 9375.0 | 2,986 | 751 | -5.0% | - | 25.2% | 331.2 |
|
Torrent Pharmaceuti…
Mar 2026 |
₹188,719.51 Cr | 4840.0 | 4,111 | 364 | +27.7% | +42.2% | 8.9% | 420.5 |
|
Cipla
Mar 2026 |
₹112,654.03 Cr | 1394.5 | 6,612 | 543 | -9.3% | - | 8.2% | 203.0 |
|
Zydus Life Science
Mar 2026 |
₹112,607.65 Cr | 1160.0 | 7,569 | 1,341 | -4.3% | - | 17.7% | 91.7 |
All amounts in ₹ Crores